RANKL enhances macrophage paracrine pro-calcific activity in high phosphate-treated smooth muscle cells: Dependence on IL-6 and TNF-α

Journal of Vascular Research

Volumn 49, Issue 6, 2012, Pages 510-521

  Deuell, Kate Ann ^a   Callegari, Andrea ^a   Giachelli, Cecilia M ^a,b   Rosenfeld, Michael E ^b   Scatena, Marta ^a  

^a University of Washington   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Cardiovascular disease; IL 6; Macrophages; RANKL; TNF ; Vascular calcification

Indexed keywords

COLONY STIMULATING FACTOR 1; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR; PHOSPHATE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL CALCIFICATION; BONE MARROW; CELL ACTIVATION; CELL CULTURE; CELL DIFFERENTIATION; COCULTURE; CONTROLLED STUDY; EXTRACELLULAR MATRIX; MACROPHAGE; MOUSE; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOOTH MUSCLE FIBER;

ANIMALS; CALCINOSIS; COCULTURE TECHNIQUES; CYTOKINES; INTERLEUKIN-6; MACROPHAGES; MICE; MYOCYTES, SMOOTH MUSCLE; OSTEOCLASTS; OSTEOPROTEGERIN; PHOSPHATES; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84865593466     PISSN: 10181172     EISSN: 14230135     Source Type: Journal    
DOI: 10.1159/000341216     Document Type: Article

References (47)

1. Sage AP, Tintut Y, Demer LL: Regulatory mechanisms in vascular calcification. Nat Rev Cardiol 2010; 7:528-536.
2. Moe SM, Reslerova M, Ketteler M, O'Neill K, Duan D, Koczman J, Westenfeld R, Jahnen-Dechent W, Chen NX: Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). Kidney Int 2005; 67:2295-2304. (Pubitemid 41623389)
3. Shao JS, Cheng SL, Sadhu J, Towler DA: Inflammation and the osteogenic regulation of vascular calcification: a review and perspective. Hypertension 2010; 55:579-592.
4. Abedin M, Tintut Y, Demer LL: Vascular calcification: mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol 2004; 24:1161-1170. (Pubitemid 38880003)
5. Rattazzi M, Bennett BJ, Bea F, Kirk EA, Ricks JL, Speer M, Schwartz SM, Giachelli CM, Rosenfeld ME: Calcification of advanced atherosclerotic lesions in the innominate arteries of ApoE-deficient mice: potential role of chondrocyte-like cells. Arterioscler Thromb Vasc Biol 2005; 25:1420-1425. (Pubitemid 40923362)
6. Lau WL, Pai A, Moe SM, Giachelli CM: Direct effects of phosphate on vascular cell function. Adv Chronic K idney Dis 2011; 18:105-112.
7. Lau WL, Festing MH, Giachelli CM: Phosphate and vascular calcification: emerging role of the sodium-dependent phosphate co-transporter PiT-1. Thromb Haemost 2010; 104:464-470.
8. Boyle JJ, Bowyer DE, Weissberg PL, Bennett MR: Human blood-derived macrophages induce apoptosis in human plaque-derived vascular smooth muscle cells by Fas-ligand/Fas interactions. Arterioscler Thromb Vasc Biol 2001; 21:1402-1407. (Pubitemid 34219799)
9. Tintut Y, Patel J, Territo M, Saini T, Parhami F, Demer LL: Monocyte/macrophage regulation of vascular calcification in vitro. Circulation 2002; 105:650-655. (Pubitemid 34123443)
10. Tintut Y, Patel J, Parhami F, Demer LL: Tumor necrosis factor-alpha promotes in vitro calcification of vascular cells via the cAMP pathway. Circulation 2000; 102:2636-2642.
11. Shioi A, Katagi M, Okuno Y, Mori K, Jono S, Koyama H, Nishizawa Y: Induction of bonetype alkaline phosphatase in human vascular smooth muscle cells: roles of tumor necrosis factor-alpha and oncostatin M derived from macrophages. Circ Res 2002; 91:9-16. (Pubitemid 34778936)
12. Yun TJ, Chaudhary PM, Shu GL, Frazer JK, Ewings MK, Schwartz SM, Pascual V, Hood LE, Clark EA: OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40. J Immunol 1998; 161:6113-6121. (Pubitemid 28535982)
13. Yun TJ, Tallquist MD, Aicher A, Rafferty KL, Marshall AJ, Moon JJ, Ewings ME, Mohaupt M, Herring SW, Clark EA: Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function. J Immunol 2001; 166:1482-1491. (Pubitemid 32114626)
14. Dhore CR, Cleutjens JP, Lutgens E, Cleutjens KB, Geusens PP, Kitslaar PJ, Tordoir JH, Spronk HM, Vermeer C, Daemen MJ: Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2001; 21: 1998-20 03. (Pubitemid 34219753)
15. Sandberg WJ, Yndestad A, Øie E, Smith C, Ueland T, Ovchinnikova O, Robertson AK, Müller F, Semb AG, Scholz H, Andreassen AK, Gullestad L, Damås JK, Frøland SS, Hansson GK, Halvorsen B, Aukrust P: Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization. Arterioscler Thromb Vasc Biol 20 06; 26:857-863. (Pubitemid 43732163)
16. Bennett BJ, Scatena M, Kirk EA, Rattazzi M, Varon RM, Averill M, Schwartz SM, Giachel-li CM, Rosenfeld ME: Osteoprotegerin inac-tivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/-mice. Arterioscler Thromb Vasc Biol 2006; 26:2117-2124. (Pubitemid 44253797)
17. Morony S, Tintut Y, Zhang Z, Cattley RC, Van G, Dwyer D, Stolina M, Kostenuik PJ, Demer LL: Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice. Circulation 2008; 117:411-420.
18. Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, Teepe MC, DuBose RF, Cosman D, Galibert L: A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997; 390:175-179. (Pubitemid 27507987)
19. Wong BR, Rho J, Arron J, Robinson E, Orl-inick J, Chao M, Kalachikov S, Cayani E, Bartlett FS, Frankel WN, Lee SY, Choi Y: TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem 1997; 272:25190-25194. (Pubitemid 27415705)
20. Speer MY, Chien YC, Quan M, Yang HY, Vali H, McKee MD, Giachelli CM: Smooth muscle cells deficient in osteopontin have enhanced susceptibility to calcification in vitro. Cardiovasc Res 2005; 66:324-333. (Pubitemid 40471047)
21. Li X, Speer MY, Yang H, Bergen J, Giachelli CM: Vitamin D receptor activators induce an anticalcific paracrine program in macrophages: requirement of osteopontin. Arte-rioscler Thromb Vasc Biol 2010; 30:321-326.
22. Sangiorgi G, Rumberger JA, Severson A, Edwards WD, Gregoire J, Fitzpatrick LA, Schwartz RS: Arterial calcification and not lumen stenosis is highly correlated with atherosclerotic plaque burden in humans: a his-tologic study of 723 coronary artery segments using nondecalcifying methodology. J Am Coll Cardiol 1998; 31:126-133. (Pubitemid 28064732)
23. Panizo S, Cardus A, Encinas M, Parisi E, Val-cheva P, López-Ongil S, Coll B, Fernandez E, Valdivielso JM: RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway. Circ Res 2009; 104:1041-1048.
24. Wada T, McKee MD, Steitz S, Giachelli CM: Calcification of vascular smooth muscle cell cultures: inhibition by osteopontin. Circ Res 1999; 84:166-178. (Pubitemid 29070112)
25. Yao Y, Watson AD, Ji S, Boström KI: Heat shock protein 70 enhances vascular bone morphogenetic protein-4 signaling by binding matrix Gla protein. Circ Res 2009; 105:575-584.
26. Jono S, Otsuki S, Higashikuni Y, Shioi A, Mori K, Hara K, Hashimoto H, Ikari Y: Serum osteoprotegerin levels and long-term prognosis in subjects with stable coronary artery disease. J Thromb Haemost 2010; 8:1170-1175.
27. Schoppet M, Sattler AM, Schaefer JR, Her-zum M, Maisch B, Hofbauer LC: Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab 2003; 88:1024-1028. (Pubitemid 36337751)
28. Ueland T, Yndestad A, Øie E, Florholmen G, Halvorsen B, Frøland SS, Simonsen S, Chris-tensen G, Gullestad L, Aukrust P: Dysregu-lated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation 2005; 111:2461-2468. (Pubitemid 40696134)
29. Kiechl S, Schett G, Schwaiger J, Seppi K, Eder P, Egger G, Santer P, Mayr A, Xu Q, Willeit J: Soluble receptor activator of nuclear factorkappa B ligand and risk for cardiovascular disease. Circulation 2007; 116:385-391. (Pubitemid 47196543)
30. Jørgensen L, Hansen JB, Brox J, Mathiesen E, Vik A, Jacobsen BK: Serum osteoprotegerin levels are related to height loss: the Tromsø Study. Eur J Epidemiol 2011; 26:305-312.
31. Fahrleitner-Pammer A, Dobnig H, Dimai HP, Holzer H, Benesch T, Borchhardt K, Ce-jka D, Haas M: The effect of RANKL and OPG on bone mineral density in pre-dialysis chronic renal failure. Clin Nephrol 2009; 71:652-659.
32. Collin-Osdoby P, Rothe L, Anderson F, Nelson M, Maloney W, Osdoby P: Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endo-thelial cells, regulation by inflammatory cy-tokines, and role in human osteoclastogen-esis. J Biol Chem 2001; 276:20659-20672.
33. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C, Li J, Elliott R, Mc-Cabe S, Wong T, Campagnuolo G, Moran E, Bogoch ER, Van G, Nguyen LT, Ohashi PS, Lacey DL, Fish E, Boyle WJ, Penninger JM: Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through os-teoprotegerin ligand. Nature 1999; 402:304-309. (Pubitemid 129516268)
34. Byon CH, Sun Y, Chen J, Yuan K, Mao X, Heath JM, Anderson PG, Tintut Y, Demer LL, Wang D, Chen Y: Runx2-upregulated receptor activator of nuclear factor KB ligand in calcifying smooth muscle cells promotes migration and osteoclastic differentiation of macrophages. Arterioscler Thromb Vasc Biol 2011; 31:1387-1396.
35. Tseng W, Graham LS, Geng Y, Reddy A, Lu J, Effros RB, Demer L, Tintut Y: PKA-in-duced receptor activator of NF-kappaB ligand (RANKL) expression in vascular cells mediates osteoclastogenesis but not matrix calcification. J Biol Chem 2010; 285:29925-29931.
36. McGonigle JS, Giachelli CM, Scatena M: Os-teoprotegerin and RANKL differentially regulate angiogenesis and endothelial cell function. Angiogenesis 2009; 12:35-46.
37. Min JK, Han KY, Kim EC, Kim YM, Lee SW, Kim OH, Kim KW, Gho YS, Kwon YG: Capsaicin inhibits in vitro and in vivo angiogenesis. Cancer Res 2004; 64:644-651. (Pubitemid 38120905)
38. Bobryshev Y V, Taksir T, Lord RS, Freeman MW: Evidence that dendritic cells infiltrate atherosclerotic lesions in apolipoprotein E-deficient mice. Histol Histopathol 2001; 16:801-808. (Pubitemid 32700390)
39. Llodrá J, Angeli V, Liu J, Trogan E, Fisher EA, Randolph GJ: Emigration of monocyte-de-rived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques. Proc Natl Acad Sci USA 2004; 101:11779-11784. (Pubitemid 39095371)
40. Yilmaz A, Lochno M, Traeg F, Cicha I, Reiss C, Stumpf C, Raaz D, Anger T, Amann K, P robst T, Ludwig J, Daniel WG, Garlichs CD: Emergence of dendritic cells in rupture-prone regions of vulnerable carotid plaques. Atherosclerosis 2004; 176:101-110. (Pubitemid 39078651)
41. Seshasayee D, Wang H, Lee WP, Gribling P, Ross J, Van Bruggen N, Carano R, Grewal IS: A novel in vivo role for osteoprotegerin li-gand in activation of monocyte effector function and inflammatory response. J Biol Chem 2004; 279:30202-30209. (Pubitemid 38937945)
42. Al-Aly Z, Shao JS, Lai CF, Huang E, Cai J, Behrmann A, Cheng SL, Towler DA: Aortic Msx2-Wnt calcification cascade is regulated by TNF-alpha-dependent signals in diabetic Ldlr-/-mice. Arterioscler Thromb Vasc Biol 2007; 27:2589-2596. (Pubitemid 350158910)
43. Xanthoulea S, Thelen M, Pöttgens C, Gijbels MJ, Lutgens E, de Winther MP: Absence of p55 TNF receptor reduces atherosclerosis, but has no major effect on angiotensin II induced aneurysms in LDL receptor deficient mice. PLoS One 2009; 4:e6113.
44. Xiao N, Yin M, Zhang L, Qu X, Du H, Sun X, Mao L, Ren G, Zhang C, Geng Y, An L, Pan J: Tumor necrosis factor-alpha deficiency retards early fatty-streak lesion by influencing the expression of inflammatory factors in apoE-null mice. Mol Genet Metab 2009; 96:239-244.
45. Okamura DM, Himmelfarb J: Tipping the redox balance of oxidative stress in fibrogen-ic pathways in chronic kidney disease. Pedi-atr Nephrol 2009; 24:2309-2319.
46. Leibbrandt A, Penninger JM: RANK/RANKL: regulators of immune responses and bone physiology. Ann NY Acad Sci 2008; 1143:123-150.
47. Rajachar RM, Truong AQ, Giachelli CM: The influence of surface mineral and osteo-pontin on the formation and function of mu-rine bone marrow-derived osteoclasts. J Mater Sci Mater Med 2008; 19:3279-3285.